Solutions to the poor efficacy of osimertinib

Osimertinib, as an important drug for the treatment of EGFR mutated non-small cell lung cancer (NSCLC), has brought hope to many patients. However, as treatment progresses, some patients may experience poor efficacy.

When osimertinib is not effective, genetic testing is crucial. Through testing, we can understand whether the patient has other genetic mutations or resistance mechanisms, thereby providing guidance for subsequent treatment. For example, if other targetable gene mutations are detected, we can consider switching to corresponding targeted drugs.

Combination therapy may be an effective strategy for patients who do not have suitable targeted drug options. Depending on the specific situation of the patient, we can consider using osimertinib in combination with other drugs such as chemotherapy drugs, immunotherapy drugs, etc., in order to achieve better therapeutic effects. This combination therapy may help overcome resistance to a single drug and improve patients' quality of life.

Local therapy is also a means to deal with the poor efficacy of osimertinib. For patients with local progression, local treatment methods such as radiotherapy can effectively control the disease and reduce the patient's symptoms. At the same time, local treatment can also be combined with systemic treatment to form a comprehensive treatment model and improve the overall treatment effect.

In addition to the above solutions, we should also pay attention to the patient's psychology and quality of life. Faced with poor efficacy, patients may develop negative emotions such as anxiety and depression. Therefore, it is also very important to provide psychological support and care to help patients establish a positive treatment attitude and life confidence.

Finally, it is important to emphasize that solutions to poor osimertinib efficacy need to be patient-specific. When formulating a treatment plan, we should fully evaluate the patient's physical condition, genetic mutation, treatment willingness and other factors to formulate a personalized treatment strategy.